Answering the Call in COPD: Practical Strategies for Improving Early Diagnosis and Patient-Centered Management in Primary Care: Pharmacologic Treatment of COPD in the Primary Care Setting #3

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity.

Release date: Thursday, May 19, 2022

Expiration date: Friday, August 19, 2022

During the period of May 19, 2022 through August 19, 2022 participants must:

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

 

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

This program has been developed in collaboration with International Primary Care Respiratory Group (IPCRG) and COPD Foundation.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

TOPIC

Pharmacologic Treatment of COPD in the Primary Care Setting

PROGRAM OVERVIEW

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, many patients receive a delayed diagnosis or remain undiagnosed and face dismal outcomes. Additionally, despite the availability of several pharmacologic therapies and continually updated guideline recommendations, COPD is sub-optimally treated in current clinical practice. As a result, patients with COPD are associated with a poor quality of life, with many patients living in discomfort and experiencing debilitating exacerbations. Recently, evidence has demonstrated the utility of combination therapy in reducing exacerbations among patients with COPD and updated guidelines have identified specific patient subsets that can benefit from these approaches. Even if appropriate therapy is initiated, patients may have persistent barriers related to optimized medication delivery and adherence. Therefore, individualized evaluation of patient characteristics and associated device selection is recommended. This program will narrow in on pharmacologic treatment selection based on COPD severity, risk for acute exacerbations, and patient ability to use specific inhaler devices.

FACULTY

Steve Holmes, MD
Executive and Education Committee, Primary Care Respiratory Society​
Education Committee, IPCRG​
NHS England Regional Clinical Respiratory Lead (South West)​
Clinical Respiratory Lead, Somerset CCG​
RCGP Severn Faculty Board​
General Practitioner​
Park Medical Practice, Shepton Mallet​
Somerset, England

 

Helgo Magnussen, MD
Founder​, Pulmonary Research Institute at Lung Clinic​
Professor​, Department of Pneumology, Allergology, and Sleep Medicine​
Medizinicum Hamburg​
Hamburg, Germany

TARGET AUDIENCE

This activity is designed for clinicians working in primary care and family medicine in Europe and worldwide.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Individualize pharmacologic treatment selection based on COPD severity, risk for acute exacerbations, and patient ability to use specific inhaler devices

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this Other activity (multi-channel video and discussion) for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert AMA PRA Category 1 CreditsTM to an equivalent number of EACCME® credits.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Steve Holmes, MD
Speaker/Advisor: AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi, Trudell, Teva, Viatris​

Helgo Magnussen, MD
Speaker: Berlin-Cheime​
Consultant: Huma Therapeutics GmbH, NDD Medical Technologies Switzerland

The IPCRG planners and managers have the following relevant financial relationships with ineligible companies:

Miguel Roman Rodriguez, MD
Advisory Board: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Pfizer, Teva
Research: AstraZeneca

Nicola Connor, Russell Emeny, Sian Williams, and Tracey Lonergan have nothing to disclose.

The COPD Foundation planners and managers having the following relevant financial relationships with ineligible companies:

Michael W. Hess, MPH, RRT, RPFT
Advisory Board: Boehringer Ingelheim
Consultant: NDD Medical
Speakers’ Bureau: Boehringer Ingelheim, Theravance Biopharma, Viatris
Writer: NDD Medical

Courtney Crim, MD
Consultant: Theravance Biopharma
Employee: GlaxoSmithKline

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Agenda

During the period of May 19, 2022 through August 19, 2022 participants must:

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.